###begin article-title 0
###xml 52 60 <span type="species:ncbi:9606">Patients</span>
nm23-H1 Protein Expression and Gene Mutation in 150 Patients with Non-Hodgkin's Lymphomas
###end article-title 0
###begin p 1
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23</italic>
###xml 644 651 644 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 761 762 761 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 813 814 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 845 852 845 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 803 811 <span type="species:ncbi:9606">patients</span>
The metastasis-suppressing role of the nm23 gene in the metastatic spread of malignant tumor is still debated. We examined the nm23-H1 protein expression and gene mutation in non-Hodgkin's lymphomas to compare with the clinicopathologic parameters. The expression of nm23-H1 protein was immunohistochemically examined in 150 cases of non-Hodgkin's lymphomas; 85 diffuse large B cell lymphomas (DLBCL), 18 marginal zone B cell lymphomas (MZL), 3 mantle cell lymphomas, 25 peripheral T cell lymphomas, not otherwise specified (TCLNOS), and 19 NK/T cell lymphomas (NK/T). Eighty-one cases (58 DLBCL, 6 MZL, 4 TCLNOS, and 13 NK/T) were studied for nm23-H1 gene mutation in exon 1 to 5. The high expression of nm23-H1 protein was associated with the high IPI score (p=0.019) and the low survival rate of the patients (p=0.0039). The gene mutation of nm23-H1 was detected in 10.3% of DLBCL and 30.7% of NK/T; but none in MZL and TCLNOS. The mutation was found in exon 1 in 5 cases, exon 2 in two cases, exon 4 in one case and both exon 1 and 2 in two cases. Our results suggest that the expression of nm23-H1 protein can be used as a poor prognostic marker in non-Hodgkin's lymphomas, and the mutational change of gene may operate in the lymphomagenesis.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23</italic>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 429 434 <span type="species:ncbi:9606">human</span>
The nm23 gene was first classified as a metastasis suppressor gene on the basis of its reduced expression in several metastatic melanoma cell lines relative to nonmetastatic counterparts (1). Subsequently, the low expression of nm23-H1 protein has been described as being linked to an increased metastatic potential in breast carcinoma, hepatoma, and gastric carcinoma, implying its role at inhibiting metastasis in a variety of human cancers (2-4). In other tumors, such as neuroblastoma, pancreatic carcinoma, and head and neck carcinomas, surprisingly, the opposite trend has been reported (5-7).
###end p 3
###begin p 4
Malignant lymphomas constitute a heterogenous group of disorders, comprising different histogenesis and variable clinical outcomes. The histologic types and clinical staging are well known as prognostic indicators. Nevertheless they cannot accurately predict a clinical outcome in an individual case. Thus, a continuous necessity for reproducible quantitative methods has been required to confer additional prognostic information and to guide the clinician in the selection of the most appropriate therapeutic approach.
###end p 4
###begin p 5
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 295 302 295 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 481 488 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
The previous studies of nm23-H1 expression in malignant lymphomas revealed that overall survival rates were significantly lower in the patients with nm23-H1-positive lymphomas than in those with nm23-H1-negative lymphomas (8-12). There has been only one study describing no mutational change of nm23-H1 gene in malignant lymphomas (13). The aims of this study are to determine the significance of nm23-H1 protein expression as a prognostic indicator and to detect the frequency of nm23-H1 gene mutation in non-Hodgkin's lymphomas.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
Materials
###end title 7
###begin p 8
###xml 488 490 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1035 1043 <span type="species:ncbi:9606">patients</span>
###xml 1078 1086 <span type="species:ncbi:9606">patients</span>
###xml 1112 1120 <span type="species:ncbi:9606">patients</span>
###xml 1133 1141 <span type="species:ncbi:9606">patients</span>
###xml 1270 1278 <span type="species:ncbi:9606">patients</span>
###xml 1438 1446 <span type="species:ncbi:9606">patients</span>
###xml 1551 1559 <span type="species:ncbi:9606">patients</span>
###xml 1709 1717 <span type="species:ncbi:9606">patients</span>
One hundred fifty non-Hodgkin's lymphomas were selected from the pathology file in the Department of Pathology, Anam and Guro Hospitals of Korea University, Korea. The tissues were routinely processed with 10% buffered formalin fixation and paraffin embedding. The diagnosis and classification of lymphomas were dependent upon the routine histologic sections and immunohistochemical staining. They were supplemented by TCRgamma rearrangement study and followed by the WHO classification (14). The studied cases were 106 B cell lymphomas (85 diffuse large B cell lymphomas [DLBCL], 18 marginal zone B cell lymphomas [MZL], and 3 mantle cell lymphomas [MCL]), and 44 T cell lymphomas (25 peripheral T cell lymphoma, not otherwise specified [TCLNOS], and 19 NK/T cell lymphomas [NK/T]). Forty-two cases were nodal and 108 cases were extranodal. The extranodal sites were 44 gastrointestinal tracts, 17 nasal cavities, 15 Waldeyer's rings, 12 ocular adnexae, 3 salivary glands, 3 thyroid glands, 3 testes, and 11 others. The median age of patients was 53.8 yr (15-88 yr). Ninty-six patients were male and fifty-four patients female. The patients were classified according to the Ann Arbor clinical staging system; 49 stage I, 58 stage II, 28 stage III, and 15 stage IV. The patients were classified according to the International Prognostic Index (IPI); 105 low risk (0, 1), 33 intermediate risk (2, 3), and 12 high risk (4, 5). Twenty-seven patients died from malignant lymphoma between 1 month to 58 months (mean; 13.7 months). One hundred twenty-three patients survived, and the mean follow-up duration was 26.9 months (2-120). This investigation was performed after obtaining an informed consent from all the patients involved in our study.
###end p 8
###begin title 9
Tissue microarray
###end title 9
###begin p 10
All slides were reviewed, and the appropriate area was marked and selected for tissue microarray. Agar blocks for tissue microarray were prepared as follows; Agar (4 g) was dissolved into 100 mL distilled water and boiled in microwave for 2 min. It was solidified in the cast and routinely processed as a tissue sample. The agar was embedded in paraffin. The selected area of each case was holed by the punch biopsy tool (2 mm in diameter) and transplanted into the agar block, holed by the same biopsy tool. After all of the cases were reembedded into the agar block, the block was incubated at 37℃ for 30 min to mould the tissue in paraffin.
###end p 10
###begin title 11
Immunohistochemical staining
###end title 11
###begin p 12
###xml 519 525 515 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
The expression of nm23-H1 protein was immunohistochemically stained on 4 microm thick section from microarray blocks by the use of LSAB method. Monoclonal antibody to nm23-H1 (1:100, Novocastra Laboratories Ltd, U.K.) was used as a primary antibody. Immunohistochemical staining results for nm23-H1 protein were classified according to the following criteria: (-), when less than 5% of tumor cells were positive; (1+), when 5-50% of tumor cells were positive; (2+), when more than 50% of the tumor cells were positive (Fig. 1).
###end p 12
###begin title 13
PCR-SSCP analysis and DNA sequencing
###end title 13
###begin p 14
###xml 883 884 863 864 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 898 901 874 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 950 952 922 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Total 81 cases (58 DLBCL, 6 MZL, 4 TCLNOS, 13 NK/T) were available for mutation study. DNA was extracted from the formalin-fixed, paraffin-embedded tissue sections by the use of the standard method with proteinase K digestion and phenol/chloroform purification. The primers for PCR were designed to amplify exons 1-5 as follows; Exon 1: (forward) 5'gtctgaaaaacgtagcgccgg3', (reverse) 5'cttaggtttgaactccggctg 3', Exon 2: (forward) 5'gcttgagacggatgacgctgta3', (reverse) 5'caggttaatcacagtgttctcc3', Exon 3: (forward) 5'atgtccttagatggtttgggggt3', (reverse) 5'tttggtctcattcatggctgtat3', Exon 4: (forward) 5'gccacattttctgctgtgatt3', (reverse) 5'cccaaatccttgtggcaact3', Exon 5; (forward) 5'gtctaatgtccatggagcttc3', (reverse) 5'cagatggtcggggatggtaac3'. The total 20 microL reaction volume contained 3 microL template, 1 microL out of each oligonucleotide primer, 2 microL dNTP, 11 microL ddH2O, 0.2 microL Taq polymerase, and 2 microL 10 x PCR buffer with Mg2+. Cycling conditions were as follows; an initial penetration at 95℃ for 5 min, 40 cycles each at 94℃ for 1 min, at 56℃ for 30 sec, at 72℃ for 30 sec, followed by one cycle at 72℃ for 10 min. PCR products were visualized by electrophoresis in 1.8% (w/v) agarose gel. Then the products were subjected to 8% non-denaturation polyacrylamide gel electrophoresis and stained with silver nitrate. DNA sequencing was performed in the cases showing abnormal bands on PCR-SSCP by the use of the Automatic Sequencer ABI 3730 (Applied Biosystem, Foster city, CA, U.S.A.).
###end p 14
###begin title 15
Statistical analysis
###end title 15
###begin p 16
###xml 307 308 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Statistical significance was evaluated by using Kruskal-Wallis test for independent groups. The survival curves were calculated by using the Kaplan-Meier method, and then compared with other prognostic variables by using a log-rank test. All statistical analyses were two-sided with a significance level of p</=0.05, and all analyses were performed by using the SPSS statistical software (version 10.0, SPSS Inc., Chicago, IL, U.S.A.).
###end p 16
###begin title 17
RESULTS
###end title 17
###begin p 18
###xml 374 381 374 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 739 746 739 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 825 826 825 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 877 884 877 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
The immunostaining for nm23-H1 protein in a reactive lymph node showed a positive reaction in the cytoplasm of centroblasts in germinal centers and transformed lymphocytes in the interfollicular area. The staining in lymphoma cells was also primarily cytoplasmic. Of the 150 non-Hodgkin's lymphomas, 58 (38.6%) cases were (2+) and 46 (30.7%) cases (1+) for nm23-H1 protein (Table 1). According to the histologic types, 45.9% of DLBCL, 16.7% of MZL, 66.7% of MCL, 28.0% of TCLNOS, and 36.8% of NK/T lymphomas were (2+). In MZL, there was a lower expression tendency of nm23-H1 protein than in other types without statistical significance. The age, sex, and the nodal or extranodal sites were not correlated with nm23-H1 protein expression (Table 2). The nm23-H1 protein expression was significantly correlated with IPI score (p=0.019) but not with the Ann Arbor clinical stage (Table 3).
###end p 18
###begin p 19
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 85 92 85 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 143 150 143 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 179 186 179 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 377 384 377 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 386 392 386 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 511 517 511 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 784 785 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 794 800 794 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
The survival rates in T cell lymphomas were worse than in B cell lymphoma (p=0.0415, Table 4). The higher Ann Arbor clinical stages (p=0.0000, Table 4), and IPI scores (p=0.0000, Table 4) were significantly associated with poor outcomes. The patients with (2+) expression of nm23-H1 protein showed the lower survival rate than those with negative or (1+) expression (p=0.0039, Table 4, Fig. 2). The high expression of nm23-H1 protein was associated with poor survival rates in B and T cell lymphomas (p=0.0013, Fig. 3). Even in the same Ann Arbor clinical stages (stage I, II and stage III, IV), and IPI groups (low, intermediate, and high), the patients with (2+) expression of nm23-H1 protein showed the lower survival rate than those with negative or (1+) expression (p=0.0042 and p=0.0483, Fig. 4).
###end p 19
###begin p 20
###xml 157 164 157 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">Table 5</xref>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 316 317 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 638 644 636 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 840 846 838 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 935 936 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
By PCR-SSCP technique, the mutations were detected in 6 cases (10.3%) out of DLBCL and 4 cases (30.7%) out of NK/T. No mutation was found in MZL and TCLNOS (Table 5). These mutations were not correlated with age (p=0.071), sex (p=0.813), nodal or extranodal sites (p=0.738), Ann Arbor clinical stage (p=0.412), IPI (p=0.239), and survival rate (p= 0.1208). The mutation sites were as follows; five cases in exon 1, two cases in exon 2, two cases in exon 1 and 2, and one case in exon 4. Sequencing was performed in eight out of ten cases. All of the four cases with exon 1 mutation showed C-->G transversion at nucleotide 55 (gi 468541) (Fig. 5). Three out of four cases with mutation in exon 2 showed insertional mutation after the nucleotide at 2257 (gi 468541) and the other one showed insertional mutation after the nucleotide at 2084 (Fig. 5). There was a weak correlation between the mutations and protein expression of nm23-H1 (p=0.057).
###end p 20
###begin title 21
DISCUSSION
###end title 21
###begin p 22
###xml 60 70 60 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 273 280 273 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 408 415 408 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 60 70 <span type="species:ncbi:7227">Drosophila</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
The human protein nm23-H1 is one of the human homologues of Drosophila awd (15). Eight different genes of this family have been identified in human, and their expressions are linked to suppression of tumor metastasis, differentiation, apoptosis, and proliferation (16,17). nm23-H1 and -H2 are nucleoside diphophate kinase, and metastasis suppression was observed in several tumor cell lines transfected with nm23-H1 gene (18,19). However, the biochemical mechanisms underlying the metastasis-suppressing action of nm23-H1 are largely unknown. The nm23 proteins are multifunctional, and they interact with many different proteins, some of which are involved in cancer progression (20). Indeed, the amount of nm23 increased in normal lymphocytes in response to mitotic stimulation and paralleled the increase in DNA synthesis (21). Our results also demonstrate the high expression of nm23-H1 protein is associated with poor prognosis. Therefore, the nm23 protein has a different and possibly varied role in tumors of different origins.
###end p 22
###begin p 23
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 18 20 18 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
Niitsu et al. (11,12) reported that serum levels of nm23-H1 in aggressive non-Hodgkin's lymphomas were significantly higher than those in controls, and that high nm23-H1 levels were correlated with poor prognosis. Moreover, Niitsu et al. (8,9) reported 58.1% (100/172 patients) of DLBCL, 33.3% (5/15 patients) of MZL, 66.7% (12/18 patients) of MCL, 25.5% (12/47 patients) of TCLNOS, and 42.9% (9/21 patients) of NK/T were strongly positive (more than 70%) for nm23-H1. The survival rates were significantly lower in the patients with nm23-H1-positive lymphomas than in those with nm23-H1-negative lymphomas.
###end p 23
###begin p 24
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
In our study, the degree of nm23-H1 protein expression was significantly correlated with IPI, but not with the age, sex, nodal or extranodal sites, and histologic types. The strong expression of nm23-H1 protein was significantly correlated with poor survival rate. Even in the same Ann Arbor clinical stage, IPI and histologic type (B and T cell lymphomas), the high expression of nm23-H1 protein was significantly correlated with poor survival rates. The results of this study were similar to the previous reports of Niistu et al. (8,9).
###end p 24
###begin p 25
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23</italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 492 499 492 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Mutational events of nm23 have not been frequently observed in human cancers, and its role in malignancy is controversial (22). Some data on colon and ovarian cancers suggested that mutations of nm23-H1 gene were associated with the presence of metastases, advanced disease, and poor survival (23,24). In neuroblastoma, a particular point mutation (Ser 120 Gly) affecting the protein folding was related to the aggressiveness (25). However, other groups were unable to detect any mutation of nm23-H1 gene in liver metastases of colon cancer, breast cancer, and hepatocellular carcinoma (3, 26-28). In malignant lymphomas, the mutational study by Aryee et al. (13) did not show any mutations by PCR-SSCP method.
###end p 25
###begin p 26
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 101 108 101 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 180 187 180 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 815 822 815 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
In this study, we evaluated the nm23-H1 gene mutation by PCR-SSCP method and sequencing. We detected nm23-H1 mutation in non-Hodgkin's lymphoma. Ten out of eighty-one cases showed nm23-H1 mutations by PCR-SSCP method. These mutations were not correlated with clinicopathologic parameters. However, interestingly enough, the mutation was only found in DLBCL and NK/T lymphomas, but not in other types. In addition, the point mutation of exon 1 and insertional mutation of exon 2 were detected at the same sites; C to G transversion at nucleotide 55 of exon 1, and insertional mutation after the nucleotide at 2257. Bafico et al. (29) reported that a common polymorphic sequence (C to T transition, 30 nucleotides upstream from the 5'splice site of exon 1) in colorectal cancers, and Cipollini et al. (22) found that nm23-H1 gene mutation (C to A transversion at nucleotide -79 of exon 1) in breast cancers. The same sequence variants as the present study have not been described so far.
###end p 26
###begin p 27
###xml 273 280 273 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
Because nm23-H1 protein can be easily examined at the time of conventional phenotypic examinations for the diagnosis of lymphoma, it may be used as a prognostic marker of non-Hodgkin's lymphoma in addition to known prognostic indicators. We found the new mutation sites in nm23-H1 gene. The role of these mutations in non-Hodgkin's lymphoma needs further investigation.
###end p 27
###begin p 28
###xml 27 49 27 49 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brain Korea 21 Project</funding-source>
This study is supported by Brain Korea 21 Project.
###end p 28
###begin article-title 29
Evidence for a novel gene associated with low tumor metastatic potential
###end article-title 29
###begin article-title 30
Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer
###end article-title 30
###begin article-title 31
###xml 61 66 <span type="species:ncbi:9606">human</span>
Reduced expression and rare genomic alteration of nm23-H1 in human hepatocellular carcinoma and hepatoma cell lines
###end article-title 31
###begin article-title 32
Expression of the nm23 gene in primary and metastatic gastric cancer tissues
###end article-title 32
###begin article-title 33
Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas
###end article-title 33
###begin article-title 34
###xml 111 116 <span type="species:ncbi:9606">human</span>
Clinicopathological features and prognostic significance of nucleoside diphosphate kinase/nm23 gene product in human pancreatic exocrine neoplasms
###end article-title 34
###begin article-title 35
Increased activity of nm23-H1 gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognosis
###end article-title 35
###begin article-title 36
Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma
###end article-title 36
###begin article-title 37
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma
###end article-title 37
###begin article-title 38
Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma
###end article-title 38
###begin article-title 39
Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma
###end article-title 39
###begin article-title 40
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma
###end article-title 40
###begin article-title 41
###xml 44 49 <span type="species:ncbi:9606">human</span>
Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness
###end article-title 41
###begin article-title 42
###xml 2 12 <span type="species:ncbi:7227">Drosophila</span>
A Drosophila gene that is homologous to a mammalian gene associated with tumor metastasis codes for a nucleoside diphosphate kinase
###end article-title 42
###begin article-title 43
nm23: unrevealing its biological function in cell differentiation
###end article-title 43
###begin article-title 44
Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions
###end article-title 44
###begin article-title 45
Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells
###end article-title 45
###begin article-title 46
Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines
###end article-title 46
###begin article-title 47
Protein interactions provide new insight into Nm23/nucleoside diphosphate kinase functions
###end article-title 47
###begin article-title 48
Proliferation-related expression of p19/nm23 nucleoside diphosphate kinase
###end article-title 48
###begin article-title 49
###xml 43 48 <span type="species:ncbi:9606">human</span>
Mutational analysis of the NM23.H1 gene in human breast cancer
###end article-title 49
###begin article-title 50
Mutation in the nm23 gene is associated with metastasis in colorectal cancer
###end article-title 50
###begin article-title 51
Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression
###end article-title 51
###begin article-title 52
###xml 20 25 <span type="species:ncbi:9606">human</span>
A point mutation of human nucleoside diphosphate kinase A found in aggressive neuroblastoma affects protein folding
###end article-title 52
###begin article-title 53
Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer
###end article-title 53
###begin article-title 54
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
Definition of regions of the human genome affected by loss of heterozygosity in primary human breast tumors
###end article-title 54
###begin article-title 55
###xml 72 77 <span type="species:ncbi:9606">human</span>
NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors
###end article-title 55
###begin article-title 56
Genomic PCR-SSCP analysis of the metastasis associated NM23-H1 (NME1) gene: a study on colorectal cancer
###end article-title 56
###begin p 57
The nm23-H1 protein expression by LSAB method. (A) (-), <5% positive cells; (B) (1+), 5-50% positive cells; (C) (2+), >50% positive cells.
###end p 57
###begin p 58
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The survival curve according to nm23-H1 protein expression (p=0.0039). -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
###end p 58
###begin p 59
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The survival curve of nm23-H1 protein expression in B cell lymphoma (A) and T cell lymphoma (B) (p=0.0013). -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
###end p 59
###begin p 60
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The survival curve of nm23-H1 protein expression according to the same Ann Arbor clinical stage (A, Stage III and IV, p=0.0042) and the same International Prognostic Index (B, IPI 2 and 3, p=0.0483).
###end p 60
###begin p 61
-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
###end p 61
###begin p 62
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
nm23-H1 mutation by sequencing. (A) All of four cases with exon 1 mutation show the point mutation at the same site (*, C <-- G). (B) Three of four cases with exon 2 mutation reveal the insertional mutation at the same site (*).
###end p 62
###begin p 63
The nm23-H1 protein expression according to the histologic types
###end p 63
###begin p 64
###xml 326 327 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
DLBCL, Diffuse large B cell lymphoma; MZL, Marginal zone B cell lymphoma; MCL, Mantle cell lymphoma; TCLNOS, Peripheral T cell lymphoma, not otherwise specified; NK/T, NK/T cell lymphoma. -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive. p=0.229.
###end p 64
###begin p 65
The nm23-H1 protein expression according to age, sex and the nodal or extranodal sites
###end p 65
###begin p 66
-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
###end p 66
###begin p 67
The nm23-H1 protein expression according to the Ann Arbor stage (Stage) and the International Prognostic Index (IPI)
###end p 67
###begin p 68
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*Value in bold type is statically significant.
###end p 68
###begin p 69
-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
###end p 69
###begin p 70
Univariate analysis of factors influencing overall survival
###end p 70
###begin p 71
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*Values in bold types are statistically significant.
###end p 71
###begin p 72
Stage, Ann Arbor stage; IPI, International Prognostic Index (IPI); -, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
###end p 72
###begin p 73
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nm23-H1</italic>
nm23-H1 mutation according to the histologic types
###end p 73
###begin p 74
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
p=0.127.
###end p 74

